Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intermediate-risk Prostate Cancer : Assessment of Hypofractionated Stereotactic Boost - Prospective Phase II Study

NCT01596816 is registered in ClinicalTrials.gov with Centre Oscar Lambret as lead sponsor.

NCT NCT01596816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01596816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intermediate-risk Prostate Cancer : Assessment of Hypofractionated Stereotactic Boost - Prospective Phase II Study
Lead sponsor
Centre Oscar Lambret
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2010
Completion date
September 1, 2018
Enrollment
76 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

cancer